Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

AIRM, NHPR, ACAD, WPI, BFS, KO - Stock Report! March 11th 2011

|Includes: ACADIA Pharmaceuticals Inc. (ACAD), AIRM


Shares of AIRM increased $4.63 (+7.92%), up to $63.08 in early today trading! AIRM, Air Methods Corp.

Air Methods Announces Year 2010 Financial Results and Provides First Quarter 2011 Update

Air ambulance service sometimes called Aeromedical Evacuation or simply Medevac is provided by a variety of different sources, in different places in the world.

The Hospital Based Services Division is the largest provider of air medical transport services for hospitals. The Community Based Services Division is one of the largest community-based providers of air medical services— The Products Division specializes in the design and manufacture of aeromedical and aerospace technology.

AIRM’s fleet of owned, leased or maintained aircraft features over 300 helicopters and fixed-wing aircraft.

For the year, AIRM's revenue increased 9% to $562.0 million compared to $514.3 million in the prior year. AIRM's Net income increased 52% to $44.1 million, or $3.50 per diluted share, in the current year from $29.0 million, or $2.33 per diluted share, in the prior year.

Read more at:

******************** NHPR, National Health Partners, Inc., NHPR.OB

The healthcare industry remains in a state of turmoil and crisis. Each year, the cost of insurance skyrockets. The need for affordable healthcare alternatives has never been greater.

According to the U.S. Census Bureau Report on Income, Poverty and Health Insurance Coverage in the United States in 2009 (Issued on September 2010)

Read more at:


ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2010

acad ACAD, ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACAD has a portfolio of four product candidates including pimavanserin, which is in Phase III development as a treatment for Parkinson’s disease psychosis. ACAD also has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, as well as a product candidate in IND-track development for schizophrenia in collaboration with Meiji Seika Kaisha.

All of the product candidates in ACAD’s pipeline emanate from discoveries made using its proprietary drug discovery platform.

ACAD reported its financial results for the fourth quarter and year ended December 31, 2010.

Read more at: